Synthesis and Antitumor Activity of Novel Hybrids of Pyrimidine/Benzimidazole Scaffolds

References

• S. Kumar, and B. Narasimhan, “Therapeutic Potential of Heterocyclic Pyrimidine Scaffolds,” Chemistry Central Journal 12, no. 1 (2018): 38–29.
   PubMedGoogle Scholar
• M. N. M. Yousif, W. A. El-Sayed, S. Abbas Hebat-Allah, H. M. Awad, and N. M. Yousif, Journal of Applied Pharmaceutical Sciences 7, no. 11 (2017): 21–32.
   Google Scholar
• S. Kumar, S. M. Lim, K. Ramasamy, V. Mani, S. A. A. Shah, and B. Narasimhan, “Design, Synthesis, Antimicrobial and Cytotoxicity Study on Human Colorectal Carcinoma Cell Line of New 4,4'-(1,4-Phenylene)Bis(Pyrimidin-2-Amine) Derivatives,” Chemistry Central Journal 12, no. 1 (2018): 73.
   PubMedGoogle Scholar
• Yan-Chun Guo, Jing Li, Jiao-Li Ma, Zhi-Ran Yu, Hai-Wei Wang, Wen-Juan Zhu, Xin-Cheng Liao, and Yu-Fen Zhao, “Synthesis and Antitumor Activity of α-Aminophosphonate Derivatives Containing Thieno[2,3-d]Pyrimidines,” Chinese Chemical Letters 26, no. 6 (2015): 755–8.
   Web of Science ®Google Scholar
• S. Kumar, A. Kaushik, B. Narasimhan, Ali. Shah S. A, S. M. Lim, K. Ramasamy, and V. Mani, “Molecular Docking, Synthesis and Biological Significance of Pyrimidine Analogues as Prospective Antimicrobial and Antiproliferative agents,” BMC Chemistry 13, no. 1 (2019): 85.
   PubMedGoogle Scholar
• Masaichi Hasegawa, Naohiko Nishigaki, Yoshiaki Washio, Kazuya Kano, Philip A. Harris, Hideyuki Sato, Ichiro Mori, Rob I. West, Megumi Shibahara, Hiroko Toyoda, et al. “Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and VEGFR-2 Tyrosine Kinase Receptors,” Journal of Medicinal Chemistry 50, no. 18 (2007): 4453–70.
   PubMed Web of Science ®Google Scholar
• Savithri Ramurthy, Sharadha Subramanian, Mina Aikawa, Payman Amiri, Abran Costales, Jeff Dove, Susan Fong, Johanna M. Jansen, Barry Levine, Sylvia Ma, et al. “Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors,” Journal of Medicinal Chemistry 51, no. 22 (2008): 7049–52.
   PubMed Web of Science ®Google Scholar
• R. Feng, Shirong Li, Caisheng Lu, C. Andreas, D. B. Stolz, M. Y. Mapara, and S. Lentzsch, "Targeting the Microtubular Network as a New Antimyeloma Strategy," Molecular Cancer Therapeutics 10, no. 10 (2011): 1886–96.
   PubMed Web of Science ®Google Scholar
• Gopal Krishna Padhy, Jagadeesh Panda, and Ajaya Kumar Behera, "Synthesis and Characterization of Novel N-Benzylbenzimidazole Linked Pyrimidine Derivatives as Anticancer Agents," Indian Journal of Pharmaceutical Education and Research 53, no. 2 (2019): 129–134.
   Google Scholar
• Heba T. Abdel-Mohsen, Fatma A. F. Ragab, Mostafa M. Ramla, and Hoda I. El Diwani, “Novel Benzimidazole-Pyrimidine Conjugates as Potent Antitumor Agents,” European Journal of Medicinal Chemistry 45, no. 6 (2010): 2336–44.
   PubMed Web of Science ®Google Scholar
• T. Toyoda, R. K. B. Brobey, G. I. Sano, T. Horii, N. Tomioka, and A. Itai, “Lead Discovery of Inhibitors of the Dihydrofolate Reductase Domain of Plasmodium Falciparum Dihydrofolate Reductase-Thymidylate Synthase,” Biochemical and Biophysical Research Communications 235, no. 3 (1997): 515–9.
   PubMed Web of Science ®Google Scholar
• Y. A. Ammar, H. M. El-Sehrawi, H. S. A. El-Zahabi, T. Z. Shawer, and M. M. F. Ismail, "Synthesis, Docking, and Antibacterial Activity of Some Novel4-Substituted s-triazino[1,2-a]benzimidazoles," Der Pharma Chemica 4, no. 5 (2012): 2140–51.
   Google Scholar
• M. M F. Ismail, N. M. Khalifa, H. H. Fahmy, H. M. El Sahrawy, and E. S. Nossier, "Anticancer Activities of a Novel Series of Polysubstituted PyrazoleDerivatives linked to Nitrogenous Heterocyclic Ring Systems," Latin American Journal of Pharmacy 35, no. 4 (2016): 740–8.
   Web of Science ®Google Scholar
• H. H. Fahmy, N. M. Khalifa, M. M F. Ismail, H. M. El Sahrawy, and E. S. Nossier, "Biological Evaluation of Novel 1,3-Diaryl-1H-Pyrazoles IncorporatingDifferent Heterocyclic Ring Systems as Potent Cytotoxic Agents," Latin American Journal of Pharmacy 35, no. 6 (2016): 1340–7.
   Web of Science ®Google Scholar
• M. M. F. Ismail, D. H. Soliman, A. M. Farrag, and R. Sabour, "Synthesis, Antitumor Activity, Pharmacophore Modeling And Qsar Studies Of Novel Pyrazoles And Pyrazolo [1, 5-A] Pyrimidines Against Breast Adenocarcinoma Mcf-7 Cell Line," International Journal of Pharmacy and Pharmaceutical Sciences 8, no. 7 (2016): 434–42.
   Google Scholar
• F. E. King, R. M. Acheson, P. C. Spensley, F. E. King, R. M. Acheson, and P. C. Spensley, “275. Benziminazole Analogues of Paludrine,” Journal of the Chemical Society (Resumed) 1366, (1948): 1366.
   Google Scholar
• S. A. M. El-Hawash, E. A. M. Badawey, and I. M. El-Ashmawey, “Nonsteroidal Antiinflammatory Agents-Part 2 Antiinflammatory, Analgesic and Antipyretic Activity of Some Substituted 3-Pyrazolin-5-Ones and 1,2,4,5,6,7-3H-Hexahydroindazol-3-Ones,” European Journal of Medicinal Chemistry 41, no. 2 (2006): 155–65.
   PubMed Web of Science ®Google Scholar
• V. P. Arya, J. David, R. S. Grewal, S. B. Marathe, and S. D. Patil, "Psychoactive Agents. 6. Synthesis And Cns Effects Of Some 2-Substituted 5-Acetyl-4-Methylpyrimidine Derivatives," Indian Journal of Chemistry 15B, (1977): 1129–32.
   Google Scholar
• M. Sharma, V. Chaturvedi, Y. K. Manju, S. Bhatnagar, K. Srivastava, S. K. Puri, and P. M. S. Chauhan, “Substituted Quinolinyl Chalcones and Quinolinyl Pyrimidines as a New Class of anti-Infective Agents,” European Journal of Medicinal Chemistry 44, no. 5 (2009): 2081–91.
   PubMed Web of Science ®Google Scholar
• Sunduru, N. Agarwal, A. Katiyar, S. B. Nishi, Goyal, N. Gupta, S. Chauhan, and P. M. S., "Synthesis of 2,4,6-trisubstituted pyrimidine and triazine heterocycles as antileishmanial agents," Bioorganic and Medicinal Chemistry 14, (2006): 7706–15.
   PubMed Web of Science ®Google Scholar
• Dieter Martin, Heinz Graubaum, Gerhard Kempter, and Werner Ehrlichmann, “Cyansäureester. 31. Umsetzungen Von 2-Guanidino-Benzimidazol Mit Elektrophilen Reagentien,” Journal Für Praktische Chemie 323, no. 2 (1981): 303–10.
   Google Scholar
• A. V. Dolzhenko, W. Chui, and A. V. Dolzhenko, “Synthesis of Ethyl 6-Aryl-4-Oxo-4,6-Dihydro-1(12)(13) h -Pyrimido-[2′,1′:4,5][1,3,5]Triazino[1,2- a ]Benzimidazole-3-Carboxylates,” Journal of Heterocyclic Chemistry 43, no. 6 (2006): 1513–21.
   Web of Science ®Google Scholar
• M. Grener, S. Schepartz, and B. Chabner, “The National Cancer Institute Cancer Drug Discovery and Development Program,” Seminars in Oncology 19, (1992): 622.
   PubMed Web of Science ®Google Scholar
• A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, and A. Vaigro-Wolff, “Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines,” Journal of the National Cancer Institute 83, no. 11 (1991): 757–66.
   PubMed Web of Science ®Google Scholar
• M. Boyd and K. Paull, “Some Practical Considerations and Applications of the National Cancer Institute in Vitro Anticancer Drug Discovery Screen,” Drug development research 34, no. 2 (1995): 91109.
   Google Scholar
• P. Magdolen, M. Meciarova, and S. Toma, “Ultrasound Effect on the Synthesis of 4-Alkyl-(Aryl)Aminobenzaldehydes,” Tetrahedron 57, no. 22 (2001): 4781–5.
   Web of Science ®Google Scholar
• K. L. Arienti, A. Brunmark, F. U. Axe, K. McClure, A. Lee, J. Blevitt, D. K. Neff, L. Huang, S. Crawford, C. R. Pandit, et al. “Checkpoint Kinase Inhibitors: SAR and Radioprotective Properties of a Series of 2-Arylbenzimidazoles,” Journal of Medicinal Chemistry 48, no. 6 (2005): 1873–85.
   PubMed Web of Science ®Google Scholar